tremelimumab astrazeneca
astrazeneca ab - tremelimumab - Καρκίνωμα, μη μικροκυτταρικός πνεύμονας - Αντινεοπλασματικοί παράγοντες - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.
columvi
roche registration gmbh - glofitamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl), after two or more lines of systemic therapy.
elahere inj.so.inf 5 mg/ml (100 mg/20 ml)
inj.so.inf (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ) - 5 mg/ml (100 mg/20 ml) - mirvetuximab soravtansine
imjudo c/s.sol.in 20mg/ml
tremelimumab - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 20mg/ml - tremelimumab 20mg - tremelimumab
talvey
janssen-cilag international n.v. - talquetamab - Πολλαπλό μυέλωμα - Αντινεοπλασματικοί παράγοντες - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
columvi c/s.sol.in 10mg/10ml (1mg/ml)
glofitamab - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 10mg/10ml (1mg/ml) - glofitamab 10mg - glofitamab
columvi c/s.sol.in 2,5mg/2,5ml (1mg/ml)
glofitamab - c/s.sol.in (ΠΥΚΝΟ ΔΙΑΛΥΜΑ ΓΙΑ ΠΑΡΑΣΚΕΥΗ ΔΙΑΛΥΜΑΤΟΣ ΠΡΟΣ ΕΓΧΥΣΗ) - 2,5mg/2,5ml (1mg/ml) - glofitamab 2,5mg - glofitamab
tepkinly
abbvie deutschland gmbh & co. kg - epcoritamab - lymphoma, large b-cell, diffuse - Αντινεοπλασματικοί παράγοντες - tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) after two or more lines of systemic therapy.
talvey inj.sol 40 mg/1 ml
talquetamab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 40 mg/1 ml - talquetamab 40mg - talquetamab
talvey inj.sol 2mg/ml
talquetamab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 2mg/ml - talquetamab 2mg - talquetamab